Lisata Therapeutics Net Income
| LSTA Stock | USD 4.57 0.02 0.44% |
As of the 17th of February 2026, Lisata Therapeutics secures the Risk Adjusted Performance of 0.1254, mean deviation of 3.89, and Downside Deviation of 2.33. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lisata Therapeutics, as well as the relationship between them.
Lisata Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 17.2673 | Revenue | Earnings Share (2.13) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -18 M | -18.9 M | |
| Net Loss | -18 M | -18.9 M | |
| Net Loss | -24.7 M | -26 M | |
| Net Loss | (2.76) | (2.90) | |
| Net Income Per E B T | 0.87 | 0.51 |
Lisata | Net Income | Build AI portfolio with Lisata Stock |
Analyzing Lisata Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Lisata Therapeutics's current valuation and future prospects.
Latest Lisata Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Lisata Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Lisata Therapeutics financial statement analysis. It represents the amount of money remaining after all of Lisata Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Lisata Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lisata Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (19.98 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Lisata Net Income Regression Statistics
| Arithmetic Mean | (28,991,137) | |
| Geometric Mean | 24,797,737 | |
| Coefficient Of Variation | (84.27) | |
| Mean Deviation | 18,894,005 | |
| Median | (20,840,000) | |
| Standard Deviation | 24,430,760 | |
| Sample Variance | 596.9T | |
| Range | 103.9M | |
| R-Value | 0.28 | |
| Mean Square Error | 588.5T | |
| R-Squared | 0.08 | |
| Significance | 0.29 | |
| Slope | 1,330,630 | |
| Total Sum of Squares | 9549.8T |
Lisata Net Income History
Other Fundumenentals of Lisata Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Lisata Therapeutics Net Income component correlations
Lisata Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Lisata Therapeutics is extremely important. It helps to project a fair market value of Lisata Stock properly, considering its historical fundamentals such as Net Income. Since Lisata Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lisata Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lisata Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. Expected growth trajectory for Lisata significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Lisata Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lisata Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lisata Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lisata Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Lisata Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Lisata Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Lisata Therapeutics.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Lisata Therapeutics on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Lisata Therapeutics or generate 0.0% return on investment in Lisata Therapeutics over 90 days. Lisata Therapeutics is related to or competes with MetaVia, NuCana PLC, Enlivex Therapeutics, Passage Bio, Exicure, CASI Pharmaceuticals, and Pelthos Therapeutics. Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellula... More
Lisata Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Lisata Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Lisata Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.33 | |||
| Information Ratio | 0.1376 | |||
| Maximum Drawdown | 88.91 | |||
| Value At Risk | (3.90) | |||
| Potential Upside | 5.58 |
Lisata Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lisata Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Lisata Therapeutics' standard deviation. In reality, there are many statistical measures that can use Lisata Therapeutics historical prices to predict the future Lisata Therapeutics' volatility.| Risk Adjusted Performance | 0.1254 | |||
| Jensen Alpha | 1.43 | |||
| Total Risk Alpha | 0.7581 | |||
| Sortino Ratio | 0.6505 | |||
| Treynor Ratio | 0.6372 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lisata Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lisata Therapeutics February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1254 | |||
| Market Risk Adjusted Performance | 0.6472 | |||
| Mean Deviation | 3.89 | |||
| Semi Deviation | 1.33 | |||
| Downside Deviation | 2.33 | |||
| Coefficient Of Variation | 694.73 | |||
| Standard Deviation | 11.03 | |||
| Variance | 121.59 | |||
| Information Ratio | 0.1376 | |||
| Jensen Alpha | 1.43 | |||
| Total Risk Alpha | 0.7581 | |||
| Sortino Ratio | 0.6505 | |||
| Treynor Ratio | 0.6372 | |||
| Maximum Drawdown | 88.91 | |||
| Value At Risk | (3.90) | |||
| Potential Upside | 5.58 | |||
| Downside Variance | 5.44 | |||
| Semi Variance | 1.78 | |||
| Expected Short fall | (5.61) | |||
| Skewness | 7.26 | |||
| Kurtosis | 56.43 |
Lisata Therapeutics Backtested Returns
Lisata Therapeutics is very risky given 3 months investment horizon. Lisata Therapeutics has Sharpe Ratio of 0.16, which conveys that the firm had a 0.16 % return per unit of risk over the last 3 months. We were able to interpolate and analyze data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.8% are justified by taking the suggested risk. Use Lisata Therapeutics Risk Adjusted Performance of 0.1254, mean deviation of 3.89, and Downside Deviation of 2.33 to evaluate company specific risk that cannot be diversified away. Lisata Therapeutics holds a performance score of 12 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 2.48, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Lisata Therapeutics will likely underperform. Use Lisata Therapeutics expected short fall, and the relationship between the value at risk and daily balance of power , to analyze future returns on Lisata Therapeutics.
Auto-correlation | 0.04 |
Virtually no predictability
Lisata Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Lisata Therapeutics time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Lisata Therapeutics price movement. The serial correlation of 0.04 indicates that only as little as 4.0% of current Lisata Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.04 | |
| Spearman Rank Test | 0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 1.37 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Lisata Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Lisata Therapeutics reported net income of (19.98 Million). This is 105.86% lower than that of the Biotechnology sector and 128.53% lower than that of the Health Care industry. The net income for all United States stocks is 103.5% higher than that of the company.
Lisata Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lisata Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lisata Therapeutics could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics of similar companies.Lisata Therapeutics is currently under evaluation in net income category among its peers.
Lisata Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lisata Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lisata Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Lisata Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Lisata Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Lisata Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lisata Therapeutics' value.| Shares | Ubs Group Ag | 2025-06-30 | 7.1 K | Royal Bank Of Canada | 2025-06-30 | 5.9 K | Founders Capital Management Inc | 2025-06-30 | 2 K | Tower Research Capital Llc | 2025-06-30 | 1.3 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 224 | Sbi Securities Co Ltd | 2025-06-30 | 140 | Barclays Plc | 2025-06-30 | 4.0 | Cheviot Value Management, Inc. | 2025-06-30 | 3.0 | Wells Fargo & Co | 2025-06-30 | 0.0 | Vanguard Group Inc | 2025-06-30 | 254.2 K | Bml Capital Management Llc | 2025-06-30 | 209.8 K |
Lisata Fundamentals
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.42 | ||||
| Operating Margin | (18.77) % | ||||
| Current Valuation | 18.39 M | ||||
| Shares Outstanding | 8.82 M | ||||
| Shares Owned By Insiders | 19.67 % | ||||
| Shares Owned By Institutions | 8.16 % | ||||
| Number Of Shares Shorted | 27.9 K | ||||
| Price To Book | 2.33 X | ||||
| Price To Sales | 37.67 X | ||||
| Revenue | 1000 K | ||||
| Gross Profit | 1.07 M | ||||
| EBITDA | (22.23 M) | ||||
| Net Income | (19.98 M) | ||||
| Cash And Equivalents | 72.99 M | ||||
| Cash Per Share | 18.07 X | ||||
| Total Debt | 137 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 22.33 X | ||||
| Book Value Per Share | 1.98 X | ||||
| Cash Flow From Operations | (19.36 M) | ||||
| Short Ratio | 0.08 X | ||||
| Earnings Per Share | (2.13) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 11.33 | ||||
| Number Of Employees | 26 | ||||
| Beta | 1.27 | ||||
| Market Capitalization | 40.31 M | ||||
| Total Asset | 35 M | ||||
| Retained Earnings | (548.07 M) | ||||
| Working Capital | 28.96 M | ||||
| Net Asset | 35 M |
About Lisata Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lisata Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lisata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lisata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lisata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lisata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lisata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lisata Therapeutics Stock:Check out For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. Expected growth trajectory for Lisata significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Lisata Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lisata Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lisata Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lisata Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.